# QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)

> **NCT01782326** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 3362 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** QVA149
- **DRUG:** Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)

## Key facts

- **NCT ID:** NCT01782326
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 3362 (ACTUAL)
- **Last updated:** 2016-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01782326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01782326, "QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01782326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*